Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer

touchEXPERT OPINIONS for touchONCOLOGY

An oncologist, a nurse and a urologist share their insights on the risks and benefits of androgen deprivation therapy, the barriers to equitable care and how to improve treatment adherence for patients with prostate cancer.

 The experts

• Dr Tanya Dorff, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
• Ms Brenda Martone, Northwestern Medicine, Chicago, IL, USA
• Dr Stephen Freedland, Cedars-Sinai, Los Angeles, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Pfizer Inc. and is jointly provided by USF Health and touchIME.

For further information visit: touchoncology.com